Desoxyn vs crystal

Added: Albertina Nix - Date: 09.02.2022 18:41 - Views: 47115 - Clicks: 1241

Desoxyn may be used alone or with other medications. These are not all the possible side effects of Desoxyn. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. It has the following structural formula:. DESOXYN tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures psychological, educational, social for a stabilizing effect in children over 6 years of age with Desoxyn vs crystal behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivityemotional labilityand impulsivity.

The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing soft neurological s, learning disabilityand abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. Methamphetamine should be administered at the lowest effective dosage, and dosage should be individually adjusted.

Late evening medication should be avoided because of the resulting insomnia. For treatment of children 6 years or older with a behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability and impulsivity: an initial dose of 5 mg DESOXYN once or twice a day is recommended.

Daily dosage may be raised in increments of 5 mg at weekly intervals until an optimum clinical response is achieved. The usual effective dose is 20 to 25 mg daily. Desoxyn vs crystal total daily dose may be given in two divided doses daily. Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy. One 5 mg tablet should be taken one-half hour before each meal. Treatment should not exceed a few weeks in duration.

Methamphetamine is not recommended for use as an anorectic agent in children under 12 years of age. The following are adverse reactions in decreasing order of severity within each category that have been reported:. Elevation of blood pressure, tachycardia and palpitation. Psychotic episodes have been rarely reported at recommended doses. Dizziness, dysphoriaoverstimulation, euphoriainsomnia, tremorrestlessness and headache. Diarrhea, constipation, dryness of mouth, unpleasant taste and other gastrointestinal disturbances.

Impotence and changes in libido ; frequent or prolonged erections. Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen. Methamphetamine may decrease the hypotensive effect of guanethidine. Concurrent administration of tricyclic antidepressants and indirect-acting sympathomimetic amines such as the amphetamines, should be closely supervised and dosage carefully adjusted. Phenothiazines are reported in the literature to antagonize the CNS stimulant action of the amphetamines.

Methamphetamine has been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended.

Abrupt cessation following prolonged high dosage administration in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with methamphetamine include severe dermatoses, marked insomnia, irritability, hyperactivityand personality changes. The most severe manifestation of chronic intoxication is psychosis often clinically indistinguishable from schizophrenia.

Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued see Drug Abuse And Dependence. Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathyserious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.

Sudden deaths, strokeand myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery diseaseor other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs.

Stimulant medications cause a modest increase in average blood pressure about mmHg and average heart rate about bpmand individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure.

Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e. Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history including assessment for a family history of sudden death or ventricular arrhythmia and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease e.

Patients who develop symptoms such as exertional chest pain, unexplained syncopeor other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation. Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

Treatment emergent psychotic or manic symptoms, e. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0. Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.

Careful follow-up of weight and height in children Desoxyn vs crystal 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months to the ages of 10 to 13 yearssuggests that consistently medicated children i. Published data are inadequate to determine whether chronic use of amphetamines Desoxyn vs crystal cause a similar suppression of growth, however, it is anticipated that they likely have this effect as Desoxyn vs crystal.

Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted. There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures.

In the presence of seizures, the drug should be discontinued. s and symptoms generally improve after reduction in dose or discontinuation of drug.

Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation e. Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. Prescribing and dispensing of methamphetamine should be limited to the smallest amount that is feasible at one time in order to minimize the possibility of overdosage.

The patient should be informed that methamphetamine may impair the ability to engage in potentially hazardous activities, such as, operating machinery or driving a motor vehicle. Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with methamphetamine and should counsel them in its appropriate use. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.

Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is available at www. Literature reports suggest that amphetamines may be associated with ificant elevation of plasma corticosteroids.

This should be considered if determination of plasma corticosteroid levels is desired in a person receiving amphetamines. Data are not available on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility. Methamphetamine has been shown to have teratogenic and embryocidal effects in mammals given high multiples of the human dose.

There are no adequate Desoxyn vs crystal well-controlled studies in pregnant women. DESOXYN tablets should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoriaincluding agitation and ificant lassitude. Amphetamines are excreted in human milk.

Mothers taking amphetamines should be advised to refrain from nursing. Safety and effectiveness for use as an anorectic agent in children below the age of 12 years have not been established. Drug treatment is not indicated in all cases of the behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivityemotional lability and impulsivity.

It should be considered Desoxyn vs crystal in light of the complete history and evaluation of the. Prescription should not depend solely on the presence of one or more of the behavioral characteristics.

Clinical experience suggests that in psychotic children, administration of DESOXYN tablets may exacerbate symptoms of behavior disturbance and thought disorder. Clinical Studies of DESOXYN did not include sufficient s of subjects age 65 years and over to determine whether elderly subjects respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy observed in this population.

Manifestations of acute overdosage with methamphetamine include restlessness, tremorhyperreflexia, rapid respirationconfusion, assaultiveness, hallucinations, panic states, hyperpyrexia, and rhabdomyolysis. Fatigue and depression usually follow the central stimulation.

Cardiovascular effects include arrhythmias, hypertension or hypotensionand circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma. Consult with a Certified Poison Control Center regarding treatment for up to date guidance and advice. Management of acute methamphetamine intoxication is largely symptomatic and includes gastric evacuation, administration of activated charcoaland sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard.

Acidification of urine increases methamphetamine excretion, but is believed Desoxyn vs crystal increase risk of acute renal failure if myoglobinuria is present. Intravenous phentolamine Regitine has been suggested for possible acute, severe hypertension, if this complicates methamphetamine overdosage.

Usually a gradual drop in blood pressure will result when sufficient sedation has been achieved. Chlorpromazine has been reported to be useful in decreasing CNS stimulation and sympathomimetic effects.

DESOXYN tablets are contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors; hypertensive crisis may result. It is also contraindicated in patients with glaucomaadvanced arteriosclerosissymptomatic cardiovascular diseasemoderate to severe hypertension, hyperthyroidism or known hypersensitivity or idiosyncrasy to sympathomimetic amines. Methamphetamine should not be given to patients who are Desoxyn vs crystal an agitated state or who have a history of drug abuse. Methamphetamine is a sympathomimetic amine with CNS stimulant activity. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions, or metabolic effects, may be involved, for example. The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week.

The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The origins of the increased weight loss due to the various possible drug effects are not established. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss. The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

The mechanism of action involved in producing the beneficial behavioral changes seen in hyperkinetic children receiving methamphetamine is unknown. In humans, methamphetamine is rapidly absorbed from the gastrointestinal tract.

Desoxyn vs crystal

email: [email protected] - phone:(863) 613-3463 x 1422

The Many Health Benefits of Meth